PI3K/Akt/mTOR signaling pathway in cancer stem cells.
Cancer stem cell
PI3K/Akt/mTOR pathway
Pathogenesis
Targeted cancer therapy
Journal
Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
24
04
2022
revised:
21
06
2022
accepted:
29
06
2022
pubmed:
18
7
2022
medline:
26
10
2022
entrez:
17
7
2022
Statut:
ppublish
Résumé
Cancer stem cells (CSCs) as a small subpopulation in tumor bulk are believed to initiate tumor formation and are responsible for the resistance to cancer therapy. The proliferation and differentiation of CSCs result in heterogeneity in a tumor which increases the chance of tumor survival and invasion. Many signaling pathways are abnormally activated or repressed in CSCs. Understanding these pathways and the metabolisms in CSCs may help targeted therapy in drug-resistant tumors. The PI3K/Akt/mTOR pathway is one of the major signaling pathways in CSCs involved in the maintenance of stemness, proliferation, differentiation, epithelial to mesenchymal transition (EMT), migration, and autophagy. Thus, suppressing the PI3K/Akt/mTOR pathway with inhibitors might be a promising strategy for targeted cancer therapy. Although the pathway is well-recognized and reviewed in tumor bulks, the functions in CSCs have not been well focused. Here, we reviewed the PI3K/Akt/mTOR signaling pathway and its functions in CSCs and addressed the potential therapeutic applications in drug-resistant tumors.
Identifiants
pubmed: 35843034
pii: S0344-0338(22)00254-0
doi: 10.1016/j.prp.2022.154010
pii:
doi:
Substances chimiques
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
MTOR protein, human
EC 2.7.1.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
154010Informations de copyright
Copyright © 2022 Elsevier GmbH. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no conflict of interest.